{"id":"0b2bf665-2b6d-5212-bb4c-b4cf41cae4d3","stable_key":"1acdb1e8-2159-5c7f-b39f-0153ff8024ae:taurine-melas-rna-response","predicate":"treatment_increases","statement":"Five patients in the ten-person MELAS trial showed a significant increase in leukocyte mitochondrial tRNA-Leu(UUR) taurine modification after high-dose taurine treatment.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"15965553-a825-56b9-a273-9ee92ed2d231","mechanism_event_label":"A molecular response was measurable in a specific mitochondrial disease.","subject":{"id":"e423cd36-f183-522b-a5e4-5f9ef50eee7e","slug":"taurine","display_name":"Taurine","entity_type_key":"small_molecule"},"object":{"id":"dd968147-5f93-56d5-bc83-7fa01f9b0e42","slug":"mt-trna-taurinomethyluridine","display_name":"Mitochondrial tRNA 5-taurinomethyluridine / tau-m5U34","entity_type_key":"rna_modification"},"evidence_count":1,"mechanism_event":{"id":"15965553-a825-56b9-a273-9ee92ed2d231","stable_key":"1acdb1e8-2159-5c7f-b39f-0153ff8024ae:taurine-melas-rna-response-event","event_type":"observed_relationship","label":"A molecular response was measurable in a specific mitochondrial disease.","description":"Five patients in the ten-person MELAS trial showed a significant increase in leukocyte mitochondrial tRNA-Leu(UUR) taurine modification after high-dose taurine treatment.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e423cd36-f183-522b-a5e4-5f9ef50eee7e","slug":"taurine","display_name":"Taurine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"dd968147-5f93-56d5-bc83-7fa01f9b0e42","slug":"mt-trna-taurinomethyluridine","display_name":"Mitochondrial tRNA 5-taurinomethyluridine / tau-m5U34","entity_type_key":"rna_modification"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Open-label 52-week study; 9 or 12 g/day under clinical supervision.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Five molecular responders among ten patients; leukocyte measurements are not direct brain-tissue measurements.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Taurine collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"taurine","display_name":"Taurine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A molecular response was measurable in a specific mitochondrial disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/29666206/ · DOI 10.1136/jnnp-2018-317964","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"daf48193-6911-5aea-b1ac-3d718b39a019","evidence_kind":"source_excerpt","locator":"Lines 281-287","start_line":281,"end_line":287,"excerpt":"## taurine-melas-rna-response\nA molecular response was measurable in a specific mitochondrial disease.\nFive patients in the ten-person MELAS trial showed a significant increase in leukocyte mitochondrial tRNA-Leu(UUR) taurine modification after high-dose taurine treatment.\nModel: Open-label 52-week study; 9 or 12 g/day under clinical supervision.\nLimitations: Five molecular responders among ten patients; leukocyte measurements are not direct brain-tissue measurements.\nEvidence access: Primary abstract\nTaurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/29666206/ · DOI 10.1136/jnnp-2018-317964","model_system":"Open-label 52-week study; 9 or 12 g/day under clinical supervision.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dc8d9ab8-fdf9-5107-877c-336cf8005097","stable_key":"import-1acdb1e8-2159-5c7f-b39f-0153ff8024ae","title":"Taurine: synthesis, transport, mitochondrial decoding and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"c6cb77619a374d9b1b04830032fdd3b33d269d160df5baba3778fad5adf57db5","revision_id":"cc45c491-cc6a-5426-ab72-d7c6d26c3614","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}